Ceftobiprole: A New Cephalosporin for MRSA Infection

Ceftobiprole had clinical cure rates similar to vancomycin plus ceftazidime for skin and skin-structure infections due to gram-negative and gram-positive organisms, including methicillin-resistant Staphylococcus aureus.

Dealing with complicated skin and skin-structure infections has become more challenging because of the emergence of antibiotic-resistant bacterial strains (particularly methicillin- resistant Staphylococcus aureus [MRSA]). Ceftobiprole, a new cephalosporin with a high affinity for penicillin-binding protein 2a, may provide another option for treating such infections. Its MIC₉₀ for MRSA is 2 µg/mL and for Enterobacteriaceae is 4 µg/mL.

In a recent industry-sponsored, multinational, randomized, double-blind trial involving 828 patients with various complicated skin and soft-tissue infections, researchers compared intravenous ceftobiprole (500 mg every 8 hours for 7–14 days) to vancomycin (1000 mg every 12 hours) plus ceftazidime (1000 mg every…

Reviewing Author

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)